Compare HSAI & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSAI | IRON |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | 733 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2021 | 2020 |
| Metric | HSAI | IRON |
|---|---|---|
| Price | $16.66 | $69.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $31.58 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.7M | 372.0K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.29 | N/A |
| Revenue Next Year | $41.32 | $283.52 |
| P/E Ratio | $61.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.69 | $40.00 |
| 52 Week High | $30.85 | $99.50 |
| Indicator | HSAI | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 52.90 |
| Support Level | $14.69 | $64.48 |
| Resistance Level | $24.05 | $71.85 |
| Average True Range (ATR) | 0.93 | 3.26 |
| MACD | -0.22 | 0.11 |
| Stochastic Oscillator | 1.48 | 60.38 |
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.